Another successful antibody-drug conjugate (ADC) looks set to roll off Daiichi Sankyo’s production line. After teasing early data on the B7-H3-directed candidate one year ago, the Japanese drugmaker has now linked DS-7300 to a 58% response rate in small cell lung cancer (SCLC) and responses in other tumors.

Grading or assessing a response rate to particular cancer therapies is admittedly an objective task. It depends on the type of cancer, the line of treatment, the dose, the side effects, and on and on. But when you near 90%, you tend to turn heads no matter the context.

The advent of blood tests that can detect multiple cancers at early stages will not only reshape how the disease is diagnosed but will bring about a major shift in the delivery of care, according to research leaders at the European Society for Medical Oncology congress 2022.

The race to develop the next generation of checkpoint inhibitors that could rival Keytruda has become one of the most watched in oncology. Who wouldn’t want a slice of the drug’s gushing multibillion-dollar revenue stream?

The FDA has found new clusters of specific types of cancer linked to the scar tissue that forms around breast implants, as part of its ongoing, yearslong review of the risks that can come with the procedure.

Allakos has achieved an undesired hat trick. Across three phase 3 trials, the biotech has now significantly reduced levels of a troublesome white blood cell without improving symptoms, driving it to rethink the development of an anti-Siglec-8 antibody that was once among the hottest prospects in biotech.

Jumping into the health and wellness sector once seemed like an easy win for some pharma companies, but the tough times are increasingly extending beyond biotech. That certainly seems to be the case for InMed Pharmaceuticals, which is backing out of the wellness arena less than a year after the Canadian drug developer acquired cannabinoid company BayMedica.

Another crop of health-focused additions to Apple’s eponymous wearable device is ready for harvest. The tech giant unveiled the new features during a keynote presentation Wednesday, with the rollout slated to begin later this month.

Silence Therapeutics’ efforts to push SLN124 as a potential treatment for myelodysplastic syndrome (MDS) may have hit a roadblock earlier this year, but the FDA appears to have faith in the therapy’s abilities for another type of blood cancer.

The legal troubles continue for Philips and the seemingly never-ending recall of around 5.5 million of its breathing support machines.